Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation

Description

The purpose of this research is to measure the extent of lung inflammation between different groups of participants using a radioactive tracer called \[18F\]NOS. A radioactive tracer is a type of imaging drug that is labeled with a radioactive tag and injected into the body.

Conditions

Smoking, Cigarette, Smoking E-cigarette, Healthy Volunteer

Study Overview

Study Details

Study overview

The purpose of this research is to measure the extent of lung inflammation between different groups of participants using a radioactive tracer called \[18F\]NOS. A radioactive tracer is a type of imaging drug that is labeled with a radioactive tag and injected into the body.

Measurement of Pulmonary Inflammation Using 18F-NOS Positron Emission Tomography (PET/CT) in E-cigarette Users

Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation

Condition
Smoking, Cigarette
Intervention / Treatment

-

Contacts and Locations

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Participants will be 18-45 years of age
  • 2. Subject must meet one of the following criteria:
  • 3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
  • 1. Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening and on scan day.
  • 2. Current untreated and unstable diagnosis of substance use disorder, except nicotine use disorder or cannabis use disorder
  • 3. Positive urine drug screen for opiates, methamphetamine or cocaine at screening
  • 4. Reported regular use of nicotine or cannabis products (except edibles) other than ENDS, cigarettes, or cannabis bowls, pipes, or blunts (e.g., smokeless tobacco, nicotine replacement therapy, wax, shatter, tinctures)
  • 5. Current unstable and/or untreated major depression or psychotic disorder per medical record review or self-reported
  • 6. Use of inhaled or oral corticosteroids or anti-inflammatory medications per medical record review or self-report
  • 7. History of lung trauma
  • 8. Active (or within the previous 4 weeks of screening) lung infection or lung disease that impact uptake of \[18F\]NOS (e.g. tuberculosis, cystic fibrosis)
  • 9. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
  • 10. Any current or past medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Pennsylvania,

Jacob Dubroff, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

2026-10-23